logo-loader
viewPressure BioSciences Inc.

Full interview: Pressure BioSciences CEO sees potential opportunity to enter clinical market after recent customer data

Pressure BioSciences Inc (OTCMKTS:PBIO) CEO Ric Schumacher tells Proactive the medical device company's signature Pressure Cycling Technology (PCT) platform has been highlighted by scientists in China and Australia, which Schumacher says could eventually propel the company into the clinical market space.

The two separate cancer research organizations, who are some of Pressure's largest customers, published findings that showcased PCT’s ability to discover biomarkers associated with cancer in tissue samples preserved from biopsies and highlighted its potential as a diagnostic tool.

Quick facts: Pressure BioSciences Inc.

Price: 1.55 USD

OTCMKTS:PBIO
Market: OTCMKTS
Market Cap: $3.53 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences Inc. named herein, including the promotion by the Company of Pressure BioSciences Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Pressure BioSciences PCT instrument deemed ‘essential’ by...

Pressure BioSciences Inc (OTCMKTS:PBIO) CEO Ric Schumacher tells Proactive the Massachusetts-based company’s patented pressure cycling technology (PCT) was featured in a presentation at the Annual Meeting of the Gynecologic Cancer Society in Brazil.  Schumacher explains the company’s PCT...

on 10/04/2019

2 min read